https://www.selleckchem.com/pr....oducts/darapladib-sb
07, CSS; P=0.54). Furthermore, the survival discriminability by BMI was greater in pStage II/III disease (P=0.006) than in pStage I disease (P=0.047). Multivariable analysis focusing on patients with pStage II/III disease showed low BMI to be independently associated with poor OS and CSS only in the non-elderly population. BMI-based evaluation was useful for predicting survival and oncological outcomes in non-elderly but not in elderly GC patients, especially in those with advanced GC. BMI-based evaluation was useful for pr
Like
Comment
Share
